| HS Code | 784045 |
| Product Name | Recombinant Newcastle Disease Virus Vaccine, Inactivated (Strain A-VII) Veterinary Grade API |
| Vaccine Type | Inactivated recombinant viral vaccine |
| Virus | Newcastle disease virus (NDV) |
| Inactivation Method | Chemically inactivated, rendering the virus non-infectious while preserving antigenicity |
| Api Form | Veterinary-grade active pharmaceutical ingredient intended for formulation into tablets, injections, capsules, powders, granules, premix, or solutions |
| Target Species | Poultry and susceptible avian species |
| Adjuvant Compatibility | Suitable for formulation with oil-emulsion or aqueous adjuvants to enhance immune response |
| Storage Conditions | Stable under refrigerated conditions (2–8°C), protected from light and freezing |
| Shelf Life | Typically 12–24 months from manufacture when stored under recommended conditions |
As an accredited Recombinant Newcastle Disease Virus Vaccine, Inactivated (Strain A-VII) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in sterilized, airtight, light-protective vials with tamper-evident seals. Quantity: 500 g per container, labeled for veterinary use. |
| Container Loading (20′ FCL) | 20′ FCL loading of temperature-controlled, inactivated recombinant Newcastle disease vaccine API, palletized and secured for safe, dry transport. |
| Shipping | Shipping requires strict cold-chain control (2–8°C) to maintain stability. Product must be packaged in validated insulated containers with gel packs, clearly labeled, and accompanied by veterinary API documentation. Ensure compliance with regional biologics transport regulations and avoid delays; expedite delivery to preserve potency and safety. |
| Storage | Store under refrigeration at 2–8°C in the original tightly closed, light-protected container. Protect from moisture and excessive heat. Do not freeze, as freezing may damage the inactivated recombinant antigen. Keep out of direct sunlight and away from veterinary feed or food contact surfaces. Use within recommended shelf life after opening. For veterinary use only. |
| Shelf Life | Shelf life: 24 months when stored at 2–8°C, protected from light, in unopened original containers. |
The inactivated recombinant Newcastle disease virus strain A-VII antigen concentrate is introduced as the aqueous-phase antigen component in water-in-oil parenteral emulsions for replacement pullets, layers, and broiler breeders. Before emulsification, the concentrate is standardized in sterile phosphate-buffered saline to a hemagglutination titre of ≥ 8 log2 per 0.1 mL; the standardized antigen phase then accounts for 20–30% v/v of the aqueous phase, and the aqueous phase is emulsified into Montanide ISA 70 VG at a 30:70 aqueous-to-oil ratio. The oil phase is preheated to 31–35 °C and pumped concurrently with the aqueous phase into a Silverson L5M-A rotor-stator homogenizer operating at 8,000–12,000 rpm with 0.5–1.0 bar back pressure. Finished emulsion is characterized by droplet D50 1.0–2.5 µm and viscosity 25–50 mPa·s at 25 °C. Terminal finished product types are monovalent inactivated NDV oil-emulsion injections filled into 500 mL or 1,000 mL multidose vials at 0.5 mL per dose. Compliance is anchored to 9 CFR 113.206, WOAH Terrestrial Manual Chapter 3.3.14 with a release expectation of ≥ 50 PD50 per dose, and Ph. Eur. 0870; sterility testing follows Ph. Eur. 2.6.1. A production-scale bottleneck observed on commercial filling lines is batch-to-batch haemagglutination titre drift after inactivation, which forces pre-blending titre correction rather than fixed-volume dilution if the final aqueous phase is to remain within the 20–30% v/v antigen fraction without exceeding the 1.0–2.5 µm emulsion droplet specification.
In inactivated combination vaccines, each antigen fraction is standardized independently before blending. The A-VII NDV component is held at ≥ 8 log2 HA per 0.1 mL, the IBV M41 component at 10^7.5 EID50 per dose before inactivation, and the EDS76 component at 10^7.0 TCID50 per dose. The three standardized fractions are combined in the aqueous phase at 10–15% v/v each, so the total antigen phase occupies 30–45% v/v of the aqueous phase; the aqueous phase remains 30% v/v of the final Montanide ISA 70 VG emulsion. NDV inactivation is performed with 0.1% v/v formalin at 37 °C for 16 h, followed by neutralisation with sodium bisulfite; IBV and EDS76 are inactivated separately under conditions validated for each virus. Blending is sequence-sensitive: the EDS76 antigen is added last to avoid aqueous-phase viscosity increase above 15 mPa·s at 20 °C, which would otherwise reduce rotor-stator emulsification efficiency. Terminal finished product types are trivalent inactivated NDV-IBV-EDS76 oil-emulsion injections for layers and breeders, filled in 500 mL vials at 0.5 mL per dose. Each fraction must meet its own monovalent release criteria; the mixed product must meet 9 CFR 113.206 for NDV and WOAH Chapter 3.3.14, while sterility and bacterial endotoxin follow Ph. Eur. 2.6.1 and Ph. Eur. 2.6.14.
Where H9N2 low-pathogenicity avian influenza and genotype VII Newcastle disease virus co-circulate, downstream manufacturers blend inactivated A-VII NDV antigen with inactivated H9 AIV antigen in a combined water-in-oil injection. The H9 fraction is standardized to 10^8.0 EID50 before inactivation, and the NDV fraction is standardized to ≥ 8 log2 HA per 0.1 mL. The blend uses 10–20% v/v of each antigen concentrate in the aqueous phase, with the aqueous phase maintained at 30% v/v of the final emulsion and a dose volume of 0.5 mL. The oil phase is Montanide ISA 70 VG; the aqueous phase includes phosphate-buffered saline with 0.01% w/v thiomersal as preservative. Emulsification is carried out at 10,000–14,000 rpm with an in-line rotor-stator device until conductivity falls below 10 µS/cm, confirming water-in-oil continuity. Terminal finished product types are bivalent injectable emulsions in 500 mL and 1,000 mL multidose vials for layer and breeder vaccination. Release testing follows 9 CFR 113.206 for the NDV fraction and WOAH Chapter 3.3.14; the H9 AIV fraction is assessed under the competent authority’s current H9 inactivated vaccine guidance because no single global monograph covers every regional H9 strain configuration.
For autogenous or emergency regional vaccines, the A-VII antigen concentrate can be transferred directly to a licensed fill-finish facility without co-antigen blending. The vaccine master file typically specifies thawing at 37 °C in a circulating water bath for not more than 15 min; repeated freeze-thaw cycles are limited to 1 to prevent HA titre loss greater than 0.5 log2. The concentrate is diluted into sterile phosphate-buffered saline to 10–20% v/v of the final aqueous phase, and the aqueous phase is emulsified in Montanide ISA 70 VG at 30:70. Low-shear magnetic stirring at 60–100 rpm is used for aqueous blending; high-shear mixing is applied only during emulsification. Batch-to-batch HA titre variance is controlled by pre-blending adjustment, because lot-specific inactivation kinetics shift residual formalin content. Compliance for autogenous product release follows the same sterility and safety requirements as licensed inactivated NDV products under 9 CFR 113.206 and WOAH Chapter 3.3.14, with additional local competent authority approval for the epidemiological justification. Terminal products are injectable oil-emulsion autogenous vaccines, usually filled in 500 mL vials.
In decentralised manufacturing layouts, the A-VII antigen concentrate is shipped as a sterile aqueous antigen premix containing 40–50% v/v concentrate, 0.01% w/v thiomersal, and phosphate-buffered saline at pH 7.2–7.4. The premix is held at 2–8 °C and transported within 72 h; on receipt, it is equilibrated to 18–22 °C for 60 min before emulsification. The oil phase is preheated to 31–35 °C; the two phases are metered at 30:70 aqueous-to-oil ratio into an in-line high-shear mixer with rotor tip speed 18–23 m/s. Final oil-emulsion injection is filled under Grade B/ISO 7 with a target fill volume 0.52 mL for a 0.5 mL dose. Terminal finished product types are monovalent oil-emulsion injections filled in 500 mL bottles. Stability of the aqueous premix is supported by sterility Ph. Eur. 2.6.1 and preservative efficacy Ph. Eur. 5.1.3; the final emulsion must still meet 9 CFR 113.206 potency requirements of ≥ 50 PD50 per dose. Tablet, capsule, granule, and dry premix presentations are not recognized downstream presentations for this inactivated viral antigen because the formalin-inactivated virion requires parenteral administration and is unstable at avian gastric pH; no WOAH, 9 CFR, or Ph. Eur. monograph defines release criteria for such solid oral forms.
When manufacturers replace mineral-oil water-in-oil adjuvants with polymer-based or water-in-oil-in-water adjuvants such as Montanide ISA 206, the allowable antigen concentrate ratio changes. In water-in-oil-in-water systems, the A-VII antigen concentrate is usually limited to 5–15% v/v of the aqueous phase because higher concentrations cause emulsion destabilisation after the second emulsification step; droplet size increases beyond 10 µm and phase separation occurs within 7 days at 37 °C. Published data for the exact droplet-size stability envelope of A-VII antigen in water-in-oil-in-water systems is limited; the stated range derives from adjuvant manufacturer technical bulletins and is not a compendial release criterion. The primary water-in-oil emulsion is prepared at 10,000–12,000 rpm; the secondary dispersion into the external aqueous phase is performed with a low-shear propeller mixer at 200–400 rpm to avoid reverse-phase inversion. Terminal finished product types are ready-to-use water-in-oil-in-water injectable emulsions, often filled in 250 mL bottles at 0.3–0.5 mL per dose. Physical stability is evaluated according to ISO 13318 for droplet size and Ph. Eur. 2.2.15 for viscosity; final product must still meet 9 CFR 113.206 potency and safety requirements.
Competitive Recombinant Newcastle Disease Virus Vaccine, Inactivated (Strain A-VII) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Recombinant Newcastle Disease Virus Vaccine, Inactivated (Strain A-VII), Veterinary Grade API is supplied as a sterile lyophilized cake or frozen aqueous suspension for further manufacture into tablets, injections, capsules, powders, granules, premixes, and solutions. The model designation used in batch documentation is NDV-AVII-API-LYO for lyophilized presentations and NDV-AVII-API-LIQ for frozen liquid presentations. The active substance is propagated in specified-pathogen-free embryonated chicken eggs and inactivated to eliminate residual infectivity while preserving haemagglutinin-neuraminidase and fusion glycoprotein immunogenicity. It is intended exclusively for incorporation into finished immunological veterinary medicinal products; it is not a ready-to-use vaccine.
The recombinant A-VII construct carries a modified fusion protein cleavage site, replacing the polybasic amino acid motif at positions 112–117 with a monobasic configuration consistent with an avirulent pathotype. Published data for this specific configuration is limited; therefore sequence verification against the manufacturer’s vector map and master seed lot documentation is required before formulation. After clarification, the allantoic harvest is inactivated with binary ethylenimine or formaldehyde under controlled pH 7.2–7.8 and temperature 20–25 °C. The inactivation cycle is validated to reduce infectivity by not less than 10^6 TCID50 per millilitre and is confirmed by three blind passages in 9–11 day-old embryonated chicken eggs.
The API is released against a panel aligned with Ph. Eur. monograph 0450 for inactivated Newcastle disease vaccine and the WOAH Terrestrial Manual Chapter 3.3.4. Because strain A-VII is a recombinant construct, batch identity is confirmed by reverse transcription polymerase chain reaction or sequencing of the modified F gene region. Conventional haemagglutination inhibition alone is not sufficient to distinguish the recombinant from other lentogenic strains. The table below summarizes representative quality attributes; final limits are defined by the manufacturer’s certificate of analysis and registration dossier.
| Quality attribute | Reference method | Typical limit |
|---|---|---|
| Appearance | Visual inspection | Off-white to pale amber lyophilized cake or clear to slightly opalescent liquid after thawing |
| Sterility | Ph. Eur. 2.6.1 | No growth |
| Mycoplasma | Ph. Eur. 2.6.7 | Negative |
| Endotoxin | Ph. Eur. 2.6.14 | < 0.5 EU per dose equivalent |
| Residual moisture | Ph. Eur. 2.2.32 | ≤ 3.0% w/w for lyophilized API |
| Residual infectivity | Three blind passages in embryonated eggs | No haemagglutinating agent recovered |
| Antigen content | Manufacturer-validated ELISA | ≥ 1.0 × 10^9 inactivated EID50 equivalents per millilitre or per gram |
| Inactivation agent residual | Validated colorimetric or chromatographic method | Formaldehyde ≤ 0.2 g/L; binary ethylenimine ≤ 5 ppm where applicable |
Dry powder and granule manufacturing requires the lyophilized API to be blended with mannitol or trehalose matrices. On a production-scale twin-shell blender, blending at 12–18 rpm for 15–20 minutes with a filling volume of 50–65% of total shell capacity is typical. Higher fill volumes reduce homogeneity for low-dose antigen blends. Fluid-bed granulation with inlet air temperature 25–30 °C and dew point below −20 °C is preferred; moisture uptake above 3.5% w/w during granulation has been associated with cake collapse and loss of haemagglutination titre. Production-scale experience with similar inactivated paramyxovirus antigens indicates that high-shear granulator tip speeds above 6 m/s can reduce haemagglutination titre by more than 0.5 log2 within 10 minutes; low-shear tumble blending is therefore specified for this API.
Enveloped virus particles are prone to surface glycoprotein unfolding at pH below 5.0 and above 8.5. In aqueous solutions intended for injection, the antigen is maintained in phosphate-buffered saline at pH 7.2–7.6 and osmolality 280–320 mOsm/kg. Ionic strength above 0.3 M sodium chloride or divalent cation concentrations above 5 mM magnesium or calcium promote particle aggregation, measured by dynamic light scattering shifts from 150–250 nm to more than 800 nm. Aggregated antigen has reduced immunogenicity and may clog 0.45 µm clarification filters during downstream processing.
Lyophilized API for tablets and capsules requires a protective matrix. Trehalose at 3–5% w/v or sucrose at 5% w/v in the bulk solution before freeze-drying preserves haemagglutination titre through the glass transition. Mannitol alone gives acceptable cake structure but often fails to protect the fusion glycoprotein during secondary drying above 25 °C. Freeze-drying cycles on production shelves typically hold product at −40 °C for 4–6 hours, ramp to −20 °C at 0.5 °C/min, and maintain secondary drying at 20–25 °C under 50–100 µbar chamber vacuum. Edge-vial moisture drift from 0.6–0.9% w/w in the centre to 1.2–1.8% w/w at the periphery is a known batch heterogeneity issue; tray loading patterns and guard vials reduce this variance.
Because the whole virus particle is 150–300 nm, terminal sterile filtration through 0.22 µm membranes cannot be used without unacceptable antigen loss. Aseptic processing is required after inactivation; all buffer components are sterilized by autoclaving or 0.22 µm filtration before antigen addition. The API itself is aseptically filled into Type I borosilicate glass vials with chlorobutyl stoppers after inactivation. For injection-grade products, the formulated vaccine is not subjected to terminal moist-heat sterilisation; terminal heat above 45 °C causes loss of haemagglutinin binding. Alcohols, quaternary ammonium compounds, and cationic surfactants at concentrations above 0.05% w/w disrupt the viral envelope and must be excluded from cleaning and formulation. Avoid amine-based buffer systems such as Tris at elevated pH; phosphate or histidine buffers are preferred.
Parenteral finished products typically use aluminium hydroxide gel or mineral oil adjuvant. The API is added after adjuvant preparation at room temperature under gentle stirring at 50–150 rpm for 30–60 minutes. High-shear rotor-stator mixing above 6,000 rpm may strip envelope glycoproteins and reduce potency. Potency of the final vaccine is expressed as protection against challenge or as serological response relative to a reference vaccine. Ph. Eur. 0450 requires a batch potency test in chickens unless an in vitro antigen quantification test has been validated against the reference method.
The recombinant A-VII strain differs from conventional lentogenic Newcastle disease virus seeds such as LaSota and VG/GA in three manufacturing-relevant respects. First, the fusion protein cleavage site is attenuated by design, not by blind passage; this creates a defined genomic sequence that can be verified by reverse transcription PCR and Sanger sequencing of the seed and working virus lot. Second, the recombinant seed may be engineered to contain a marker sequence enabling differentiation of infected from vaccinated animals using molecular assays, though this claim must be confirmed against the manufacturer’s regulatory dossier. Third, because the attenuation is genetically fixed, the master seed can be maintained under defined conditions with lower reliance on passage history.
| Property | Recombinant A-VII API | Conventional inactivated LaSota API |
|---|---|---|
| F gene cleavage motif | Modified monobasic, sequence-confirmed | Naturally lentogenic |
| Identity method | RT-PCR and sequencing | Haemagglutination inhibition and monoclonal antibody panel |
| Thermostability in lyophilized form | Matrix-dependent; no inherent advantage | Similar matrix-dependent behaviour |
| Reversion risk after inactivation | Not applicable | Not applicable |
For oral dosage forms, the inactivated antigen must be protected from gastric pH below 3.0 and pepsin-mediated proteolysis. Enteric-coated tablets for poultry oral delivery are not common; published data for this specific configuration is limited. Granules and premixes intended for drinking water or feed should be formulated with acid-resistant coatings or antacid buffers; unprotected antigen loses haemagglutination titre within 30 minutes at pH 2.0 and 37 °C. Liquid solutions must be stored at 2–8 °C and used within 24 hours of compounding. Frozen liquid at −20 °C can be stored for longer periods, but repeated freeze-thaw cycles greater than 3 are not permitted because they reduce titre. Shipment of frozen API is performed on dry ice; lyophilized API may be shipped at 2–8 °C only if the stability programme supports that condition.
